Please use this identifier to cite or link to this item:
Title: Therapeutic benefit of selective inhibition of p110α PI3-kinase in pancreatic neuroendocrine tumors
Author: Soler, Adriana
Figueiredo, Ana Raquel Martins
Castel Morales, Pau
Martín Fernández, Laura
Monelli, Erika
Angulo Urarte, Ana
Milà Guasch, Maria
Viñals Canals, Francesc
Baselga Torres, Josep, 1959-
Casanovas i Casanovas, Oriol
Graupera i Garcia-Milà, Mariona
Keywords: Pàncrees
Inhibidors de fosfodiesterases
Phosphodiesterase Inhibitors
Issue Date: 1-Dec-2016
Publisher: American Association for Cancer Research
Abstract: Purpose: mutations in the PI3K pathway occur in 16% of patients with pancreatic neuroendocrine tumors (PanNETs), which suggests that these tumors are an exciting setting for PI3K/AKT/mTOR pharmacologic intervention. Everolimus, an mTOR inhibitor, is being used to treat patients with advanced PanNETs. However, resistance tomTOR-targeted therapy is emerging partially due to the loss of mTOR-dependent feedback inhibition of AKT. In contrast, the response to PI3K inhibitors in PanNETs is unknown. Experimental Design: in the current study, we assessed the frequency of PI3K pathway activation in human PanNETs and in RIP1-Tag2 mice, a preclinical tumor model of PanNETs, and we investigated the therapeutic efficacy of inhibiting PI3K in RIP1-Tag2 mice using a combination of pan (GDC-0941) and p110 alpha-selective (GDC-0326) inhibitors and isoform-specific PI3K kinase-dead-mutant mice. Results: human and mouse PanNETs showed enhanced pAKT, pPRAS40, and pS6 positivity compared with normal tissue. Although treatment of RIP1-Tag2 mice with GDC-0941 led to reduced tumor growth with no impact on tumor vessels, the selective inactivation of the p110 alpha PI3K isoform, either genetically or pharmacologically, reduced tumor growth as well as vascular area. Furthermore, GDC-0326 reduced the incidence of liver and lymph node metastasis compared with vehicle-treated mice. We also demonstrated that tumor and stromal cells are implicated in the antitumor activity of GDC-0326 in RIP1-Tag2 tumors. Conclusions: our data provide a rationale for p110a-selective intervention in PanNETs and unravel a new function of this kinase in cancer biology through its role in promoting metastasis.
Note: Versió postprint del document publicat a:
It is part of: Clinical Cancer Research, 2016, vol. 22, num. 23, p. 5805-5817
Related resource:
ISSN: 1078-0432
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
662999.pdf3.47 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.